Essential atlas of heart diseases
著者
書誌事項
Essential atlas of heart diseases
McGraw-Hill, c2001
2nd ed
大学図書館所蔵 件 / 全5件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
"Developed by Current Medicine, Inc., Philadelphia"
内容説明・目次
内容説明
A full-color atlas designed to provide all health care professionals with a detailed pictorial presentation of cardiovascular diseases and their treatment. Updated throughout, the Second Edition highlights important points in summary boxes, and features information on new drugs and clinical trials.
目次
- Specific Changes as Described by Current Science
- Chapter 1: New figure on the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial. Added two new figures, Lipid Concentrations According to Year of Study and Treatment Group
- Kaplan-Meier Estimates of the Incidence of Death from Coronary Heart Disease and Nonfatal Myocardial Infarction in the Gemfibrozil and Placebo Groups. Chapter 2: Figure 2-15 replaced with new figure showing the systematic overview of ACE inhibitor trials post-myocardial infarction. Figure 2-18 replaced with figure listing the antithrombotic agents in acute coronary systems. Figure 2-19 replaced with figure showing the systematic overview of aspirin vs heparin clinical trials. Figure 2-28 replaced by new table on characteristics of thrombolytic agents. New figure added showing results of the Gusto III trial and Assent II trial. Figure 2-43 replaced with figure showing systematic overview of various glycoprotein Iib/IIIa inhibitors vs placebo trials in acute coronary syndromes. New figure showing outcomes of before and after percutaneous intervention in patients treated with glycoprotein Iib/IIIa inhibitors. New figure comparing direct PTCA and thrombolysis. Figure 2-51 replaced by the survivial curves from the Shock Trial. Chapter 4: New sections "Molecular and Cellular Mechanisms of Myocardial Remodeling," "Matrix remodeling," and "Inflammatory Cytokines" Chapter 7: Revise figure 7-51 to include angiotensin-receptor blockers. Added info on the Syst-Eur study, losartan, eprosartan, and dual metalloproteinase and vasopeptidase inhibitors. Chapter 8: New tables "Indications for Surgery for Severe for AS" and "Valve Selection for an Individual Patient" Chapter 9: See author's letter in your mailbox. Dr. Freedom determined that this chapter did not need updating
- Braunwald approved. Chapter 10: New figures on Manifestations of Upper-airway Closure, cardiac myxoma.
「Nielsen BookData」 より